Frederick Detorres, MD
Allergy & Immunology · Muskegon, MINPI 1518023480
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,100 of the $23,902 with a category attached, or 71.5%. GSK accounts for 76.7% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $11,484 and has fallen 91.7% since, to $951 in 2025.
Across 388 payments — averaging $61.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$18K
- AstraZeneca$1K
- Novartis$656
- Boehringer Ingelheim$474
- Regeneron Healthcare Solutions, Inc.$439
- Grifols USA, LLC$403
- plus $2K from 23 others
What the payments were for
- Speaking & faculty fees$17,10072%
- Food & beverage$6,71328%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 123 | $18,326 |
| AstraZeneca | 58 | $1,267 |
| Novartis | 34 | $656 |
| Boehringer Ingelheim | 25 | $474 |
| Regeneron Healthcare Solutions, Inc. | 19 | $439 |
| Grifols USA, LLC | 17 | $403 |
| CSL Behring | 18 | $360 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $344 |
| Genentech USA, Inc. | 11 | $249 |
| Amgen | 10 | $201 |
| Pharming Healthcare, Inc. | 6 | $144 |
| Pfizer | 6 | $128 |
| Kaleo, Inc. | 7 | $107 |
| AbbVie | 5 | $103 |
| Sanofi | 5 | $100 |
| Teva Pharmaceuticals USA, Inc. | 6 | $96 |
| Biocryst US Sales Co., LLC | 4 | $80 |
| Blueprint Medicines Corporation | 2 | $72 |
| Alk-abello, Inc | 3 | $71 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $44 |
| Mylan Specialty L.p. | 2 | $43 |
| Optinose US, Inc. | 2 | $34 |
| LEO Pharma Inc. | 2 | $33 |
| Incyte Corporation | 1 | $29 |
| Cycle Pharmaceuticals Inc | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Verona Pharma, Inc. | 1 | $22 |
| Aytu Biopharma, Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$17,100
How this compares
$23,902 in reported general payments places this provider in the 85th percentile of 119 allergy & immunology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrladeyoBerotralstat Hydrochloride | 23 | $1,013,785 |
| Dupixent SyringeDupilumab | 106 | $400,056 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 305 | $210,638 |
| Dupixent PenDupilumab | 33 | $143,292 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $116,407 |
| Spiriva RespimatTiotropium Bromide | 156 | $104,395 |
| Fasenra PenBenralizumab | 13 | $72,619 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $62,378 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 241 | $61,950 |
| Breo ElliptaFluticasone/Vilanterol | 113 | $59,797 |
| SymbicortBudesonide/Formoterol Fumarate | 166 | $48,828 |
| DuleraMometasone/Formoterol | 87 | $36,160 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 182 | $29,992 |
| Epinephrine | 89 | $23,402 |
| Incruse ElliptaUmeclidinium Bromide | 47 | $20,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Biocryst US Sales Co., LLCOrladeyo | $80 | $1,013,78523 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $18,326 | $295,794481 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $1,267 | $123,200287 claims |
| CSL BehringHizentra | $360 | $116,40713 claims |
| Boehringer IngelheimSpiriva Respimat | $474 | $104,395156 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Qnasl, Proair Respiclick | $96 | $27,442115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 119 allergy & immunology providers in Michigan.
Other allergy & immunology in Muskegon
- Wendi GrasmanMuskegon$6K
- Steven StrykCanton$949K
- Hassan NasirWest Branch$736K
- Theodore KelbelGrand Rapids$695K
- Nicholas HartogGrand Rapids$575K
- Kathleen DassOak Park$446K
- Pulin PatelMount Clemens$431K
- Alan BaptistAnn Arbor$168K
- Mohsen NasirSaginaw$99K
- Abdul Husein BahrainwalaRoyal Oak$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.